

Treatment Advice Letter

| |
|--|
| Attach patient identification Sticker |
| Title: _____ |
| First name: _____ |
| Surname: _____ |
| Patient's Address: _____ |
| _____ |
| _____ |
| D.o.b: _____ |

GP's Details:

Name: _____

Practice: _____

Known Allergies: _____

Date:

Dear Doctor,

Your patient has been diagnosed with Pulmonary Arterial Hypertension (PAH) at the Sheffield Pulmonary Vascular Disease Unit and prescribed tadalafil tablets 40mg once a daily.

Tadalafil is a Phosphodiesterase-5 Inhibitor (PDE-5I) which works for PAH by relaxing smooth muscle and subsequent vasodilatation though enhancing the action of cyclic GMP. Tadalafil is licensed to treat PAH and is endorsed by the UK National Commissioning Policy.

The treatment has already been initiated. Written information on how to take the tablets has been provided and counselling given at the hospital. Please refer to the Summary of Product Characteristics (SPC) for information on potential undesirable effects and drug interactions, before prescribing other medications to your patient.

This medication is funded by NHS England and is prescribed by the Sheffield Pulmonary Vascular Disease Unit. You should not be asked for prescriptions for this medication as the patient will be delivered all supplies and ancillaries by our Homecare Partners, Healthcare at Home (0870 600 1540) or BUPA Home Healthcare (0845 8888 235). You are advised where possible, to insert this drug onto GP repeat prescribing systems so as to highlight any potentially harmful drug interactions e.g. nitrates. There is a useful reminder on how to do this for GP practices on the [intranet](#).

If you have any queries regarding this or any aspect of their treatment, please do not hesitate to contact me on 0114 271 3259 or neil.hamilton@nhs.net.

Yours Faithfully



Neil Hamilton
Pulmonary Vascular Disease Unit Pharmacist